W
WAVEMAN · COMPANY
NTLA · Intellia Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

NTLA

Intellia Therapeutics, Inc.
PHARMA & BIOTECH · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · CIK 0001652130
FORM 144 · 2☆ WATCH
INSIDER NET · 180D
-$506.6K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
194
13F, latest reported quarter
REVENUE GROWTH
+16.9%
XBRL, annual
NET MARGIN
-609.9%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$506.6K over 180 days
-$506.6K over 90 days
below 55% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
194 funds added or opened last quarter
more than 86% of Pharma & Biotech
REVENUE
+16.9% year over year
more than 66% of Pharma & Biotech
MARGIN
-609.9% net margin
below 84% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
31.4% of shares outstanding short · 12.0 days to cover · settled 2026-07-31
the highest in Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$506.6K across 3 people in 180 days.
194 funds added or opened positions in the latest 13F quarter, of 332 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +11.8%
+11.8%12M
-29%+29%+87%+145%2025-092025-102025-122026-032026-052026-072026-09 2026-01-05 · Cohen Fred E bought $1.4M2025-12-11 · LEONARD JOHN M sold $474.1K2026-01-05 · LEONARD JOHN M sold $314.5K2025-12-11 · LEONARD JOHN M sold $310.9K2026-08-20 · LEONARD JOHN M sold $250.6K2026-01-05 · Lebwohl David sold $109.6K2026-01-05 · BASTA JAMES sold $95.8K2026-07-22 · Dulac Edward J III sold $91.2K2026-01-05 · Clark Eliana sold $87.6K2026-07-02 · Dulac Edward J III sold $84.2K2026-01-05 · Schultes Birgit C sold $78.4K2026-01-05 · Dulac Edward J III sold $58.8K2025-12-11 · LEONARD JOHN M sold $51.4K2026-07-01 · Dube Michael P sold $44.3K2026-08-21 · LEONARD JOHN M sold $36.2K2025-10-01 · Dube Michael P sold $32.5K2026-01-05 · Dube Michael P sold $27.5K2026-03-02 · BASTA JAMES sold $16.7K2026-03-02 · Clark Eliana sold $8.4K2025-10-01 · Schultes Birgit C sold $5392026-08-20 · LEONARD JOHN M filed to sell $293.6K2026-07-02 · EDWARD DULAC filed to sell $80.6K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $506.6K sold by insiders over 180 days, 194 funds added last quarter, $374.3K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Intellia Therapeutics, Inc. insiders sold a net $506.6K of stock across 142 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
LEONARD JOHN M
President and CEO
SELL
2026-08-21
2,785.0
$36.2K
LEONARD JOHN M
President and CEO
SELL
2026-08-20
19,890.0
$250.6K
Dulac Edward J III
EVP, Chief Financial Officer
SELL
2026-07-22
8,111.0
$91.2K
Dulac Edward J III
EVP, Chief Financial Officer
SELL
2026-07-02
4,677.0
$84.2K
Dube Michael P
VP, Chief Accounting Officer
SELL
2026-07-01
2,641.0
$44.3K
142 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 137 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
ARK Investment Management LLC
16,875,684.0 sh
$285.5M
BlackRock, Inc.
15,409,023.0 sh
$260.7M
STATE STREET CORP
9,234,987.0 sh
$156.3M
VANGUARD PORTFOLIO MANAGEMENT LLC
7,332,401.0 sh
$124.1M
D. E. Shaw & Co., Inc.
6,443,323.0 sh
$109.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
LEONARD JOHN M
FILED 2026-08-20
$293.6K
EDWARD DULAC
FILED 2026-07-02
$80.6K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
ARK Genomic Revolution ETF
$47.2M POSITION · AS OF 2026-04-30
3.8%
Tanaka Growth Fund
$1.4M POSITION · AS OF 2026-02-28
3.7%
American Beacon ARK Transformational Innovation Fund
$3.4M POSITION · AS OF 2026-03-31
2.2%
ARK Innovation ETF
$133.5M POSITION · AS OF 2026-04-30
2.1%
Global X Genomics & Biotechnology ETF
$621.1K POSITION · AS OF 2026-02-28
1.2%
Virtus Biotech Clinical Trials Etf
$412.5K POSITION · AS OF 2026-04-30
1.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 9 registered trials, 6 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
0 ACTIVE
3
Phase 3
3 ACTIVE
2
Not applicable
2 ACTIVE
3
Multi-phase
1 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$5.1M
$3.2M
$1.9M
-83%
+87%
2024
$15.3M
$353.5K
$4.7M
-79%
+54%
2023
$11.7M
$8.3M
$4.1M
-44%
+19%
2022
$10.1M
-$14.1M
$3.9M
-36%
-18%
2021
$9.8M
$37.8M
$7.0M
+117%
+22%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$67.7M$57.9M$36.3M$52.1M
OPERATING INCOME$-441.0M$-534.3M$-515.3M$-458.2M
NET INCOME$-412.7M$-519.0M$-481.2M$-474.2M
EPS (DILUTED)-3.81-5.25-5.42-6.16
OPERATING CASH FLOW$-394.7M$-348.9M$-394.1M$-333.3M
CASH$155.5M$189.2M$226.7M$523.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →